Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
15 June 2017 - 9:30PM
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the
appointment of Mark I. Froimson, M.D. to its board of directors.
Dr. Froimson is currently serving as the President of the American
Association of Hip and Knee Surgeons (AAHKS). Previously, he was
the Executive Vice President and Chief Clinical Officer of Trinity
Health, a major national non-profit Catholic healthcare system
comprising 93 hospitals in 22 states.
“Mark’s deep clinical expertise along with his proven executive
track record of driving medical innovation will be an exceptional
resource to Pacira as we advance our corporate mission to provide
non-opioid pain control to as many postsurgical patients as
appropriate,” said Dave Stack, chairman and chief executive officer
of Pacira. “Mark’s leadership at Trinity Health has given him
unique and relevant insights into refining patient care, especially
those at risk for opioid dependence and addiction. We welcome Mark
and look forward to his contributions to the Pacira Board of
Directors.”
Prior to his executive leadership position at Trinity Health,
Dr. Froimson was president and chief executive officer of Euclid
Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as
a staff surgeon in the Department of Orthopedic Surgery at the
Cleveland Clinic for over 16 years, during which time he held a
variety of leadership positions including president of the
professional staff, vice chair of the Orthopedic and Rheumatologic
Institute, and member of the Board of Governors and Board of
Trustees.
Dr. Froimson received a B.S. in philosophy from Princeton
University, an M.D. from Tulane University School of Medicine and
an MBA from the Weatherhead School of Business at Case Western
Reserve University. He completed his general surgical and
orthopedic training at the University of California, Los Angeles
and Columbia-Presbyterian Medical Center. He completed his
fellowship in adult reconstructive surgery at the University
Hospitals of Cleveland.
Dr. Froimson’s publications include authoring book chapters,
abstracts and articles in scientific journals, such as the Journal
of Arthroplasty, the Journal of Bone and Joint Surgery, the
Cleveland Clinic Journal of Medicine and the American Journal of
Orthopedics. In addition, he serves in an editorial capacity for
numerous scientific publications.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s flagship product,
EXPAREL® (bupivacaine liposome injectable suspension), indicated
for single-dose infiltration into the surgical site to produce
postsurgical analgesia, was commercially launched in the United
States in April 2012. EXPAREL and two other products have
successfully utilized DepoFoam®, a unique and proprietary product
delivery technology that encapsulates drugs without altering their
molecular structure, and releases them over a desired period of
time. Additional information about Pacira is available at
www.pacira.com.
Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com
Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
aschneider@coynepr.com
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From Apr 2024 to May 2024
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From May 2023 to May 2024